West Pharmaceutical Services, Inc. $WST Stock Bought by Envestnet Asset Management Inc.

Key Points

• Envestnet Asset Management increased its West Pharmaceutical Services stake by 10.2% in the second quarter, adding 24,015 shares and bringing its holdings to 259,536 shares valued at approximately $93.2 million. Institutional investors collectively own 93.9% of the company.
• West Pharmaceutical Services reported quarterly EPS of $2.37, exceeding the $2.08 analyst consensus, while revenue rose 13.8% year over year to $872.3 million. The company guided for fiscal 2026 EPS of $8.85 to $9.05.
• Analysts maintain a generally positive outlook, with 12 Buy ratings and two Holds for a consensus “Moderate Buy” rating and an average price target of $382.00. The company also declared a quarterly dividend of $0.22, equivalent to a 0.2% yield.

Envestnet Asset Management Inc. raised its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 10.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 259,536 shares of the medical instruments supplier's stock after acquiring an additional 24,015 shares during the period. Envestnet Asset Management Inc. owned approximately 0.37% of West Pharmaceutical Services worth $93,173,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Cornerstone Planning Group LLC lifted its stake in West Pharmaceutical Services by 90.9% in the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 50 shares during the last quarter. Bayban bought a new position in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $27,000. Avalon Trust Co purchased a new stake in shares of West Pharmaceutical Services in the second quarter worth approximately $28,000. Addison Advisors LLC bought a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $28,000. Finally, Raiffeisen Bank International AG lifted its stake in shares of West Pharmaceutical Services by 95.6% during the 2nd quarter. Raiffeisen Bank International AG now owns 133 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 65 shares during the last quarter. Institutional investors own 93.90% of the company's stock.

West Pharmaceutical Services Stock Performance

WST stock opened at $370.62 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The business has a 50-day moving average price of $350.22 and a 200 day moving average price of $318.54. The company has a market capitalization of $26.08 billion, a P/E ratio of 47.45, a PEG ratio of 2.59 and a beta of 1.14. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same quarter last year, the firm posted $1.84 EPS. The company's revenue for the quarter was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities research analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services's payout ratio is presently 11.27%.

Wall Street Analyst Weigh In

WST has been the topic of a number of recent analyst reports. Zacks Research lowered West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 12th. BNP Paribas Exane assumed coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They set an "outperform" rating and a $447.00 target price for the company. TD Cowen restated a "buy" rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. UBS Group raised their price target on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. Finally, Barclays upgraded shares of West Pharmaceutical Services from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Twelve research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, West Pharmaceutical Services presently has a consensus rating of "Moderate Buy" and an average price target of $382.00.

Insider Activity at West Pharmaceutical Services

In related news, VP Annette Favorite sold 8,135 shares of the company's stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the completion of the sale, the vice president directly owned 16,845 shares in the company, valued at $5,740,944.45. This represents a 32.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Over the last three months, insiders sold 15,659 shares of company stock valued at $5,443,749. Insiders own 0.60% of the company's stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc NYSE: WST develops and manufactures components and systems used to package, contain and deliver injectable medicines and other healthcare products. Its customers include pharmaceutical, biotechnology and medical device companies, which use West products in drug administration and medical applications.

The company's offerings include elastomer components such as stoppers, plungers and seals; syringe and cartridge components; vial and container closure systems; and specialized delivery systems for injectable and other complex medicines.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.